1- Project Name: Development of Recombinant Protein Based Vaccine Against SARS-Cov-2

Aim: The main aim of our project is to develop a recombinant protein based vaccine which contains viral antigens, as a whole or partially, which would induce permanent neutraliser antibodies in the bodies of vaccinated people.

Supported By: TUBITAK

2- Project Name: Development of “Ghost Receptor-Antibody” Based Drug Against SARS-Cov2

Aim: We aim to produce a drug that will capture the free virus particles in the bodily fluids and disable the SARS-Cov-2 virus via disintegrating it. The drug will contain the recombinant proteins produced in our labs, which are defined as “ghost receptor-antibodies” by us.

Supported By: TUBITAK